Earnings ·
Pacira BioSciences reported second quarter 2026 total revenue of $192.4 million, a 6 percent year-over-year increase…
PCRXPacira BioSciences, Inc.
Pacira BioSciences reported second quarter 2026 total revenue of $192.4 million, a 6 percent year-over-year increase, driven by EXPAREL net product sales of $147.8 million and ZILRETTA sales of $32.6 million. The company achieved GAAP net income of $4.7 million ($0.12 per share) and non-GAAP net income of $29.5 million ($0.73 diluted per share). Pacira closed the divestiture of its iovera° business to Zimmer Biomet on July 31, 2026, receiving $73.6 million in cash after adjustments, with up to $70 million in potential future milestones. The company updated its full-year 2026 total revenue guidance to $735–$760 million and reiterated EXPAREL sales guidance of $600–$620 million. Pacira BioSciences is a biopharmaceutical company focused on innovative non-opioid pain therapies.